Document is current

Any future updates will be listed below

Modeling and Simulation to Support Phase 2 Dose Selection for RG7652, a Fully Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9

Crossref DOI link: https://doi.org/10.1208/s12248-015-9750-8

Published Online: 2015-03-31

Published Print: 2015-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark